Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
News|Articles|March 31, 2026
Q1 2026 recap: 6 FDA approvals pediatricians need to know
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Patrick Campbell, Yasmeen Qahwash
A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.
Advertisement
Advertisement
The first quarter of 2026 marked a period of profound advancement in pediatric health care, driven by a wave of FDA drug approvals that offer renewed hope for some of the most complex and rare pediatric conditions. From historic, first-of-their-kind systemic therapies for ultrarare disorders such as Menkes disease and Hunter syndrome to critical new interventions for achondroplasia and acquired hypothalamic
Related to this article
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.
Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
FDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules.
Advertisement
Advertisement